Generic placeholder image

Current Cardiology Reviews

Author(s): Asra K. Butt*, Jay Patel , Hamid Shirwany, Qasim Mirza, Jonathan Hoover and Rami N. Khouzam

DOI: 10.2174/1573403X17666211015145132

DownloadDownload PDF Flyer Cite As
Beneficial Extracardiac Effects of Cardiovascular Medications

Article ID: e151021197270 Pages: 17

  • * (Excluding Mailing and Handling)

Abstract

Cardiovascular diseases are the most common cause of death worldwide, with cardiovascular medications being amongst the most common medications prescribed. These medications have diverse effects on the heart, vascular system, as well as other tissues and organ systems. The extra cardiovascular effects have been found to be of use in the treatment of non-cardiovascular diseases and pathologies. Minoxidil is used to manage systemic hypertension with its well-known side effect of hirsutism used to treat alopecia and baldness. Sildenafil was originally investigated as a treatment option for systemic hypertension; however, its side effect of penile erection led to it being widely used for erectile dysfunction. Alpha-1 blockers such as terazosin are indicated to treat systemic hypertension but are more commonly used for benign prostatic hyperplasia and post-traumatic stress disorder. Beta blockers are the mainstay treatment for congestive heart failure and systemic hypertension but have been found useful to help in patients with intention tremors as well as prophylaxis of migraines. Similarly, calcium channel blockers are indicated in medical expulsion therapy for ureteric calculi in addition to their cardiovascular indications. Thiazides are commonly used for treating systemic hypertension and as diuretics. Thiazides can cause hypocalciuria and hypercalcemia. This side effect has led to thiazides being used to treat idiopathic hypercalciuria and associated nephrolithiasis. Spironolactone is commonly utilized in treating heart failure and as a diuretic for edema. It’s well described anti-androgen side effects have been used for acne vulgaris and hirsutism in polycystic ovarian syndrome. This review article discusses how the various extracardiovascular effects of commonly used cardiovascular medications are put to use in managing non-cardiovascular conditions.

Keywords: Pharmacotherapy, cardiovascular disease, medications, side effects, extracardiovascular, beneficial effects.

Graphical Abstract

[1]
Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
[2]
Centers for Disease Control and Prevention. Underlying Cause of Death, 1999–2018 CDC WONDER Online Database. Atlanta, GA: Centers for Disease Control and Prevention 2018.
[3]
Fryar CD, Chen T-C, Li X. Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010 pdf icon [PDF-494K 2012.
[4]
Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med 1980; 303(25): 1480-1.
[http://dx.doi.org/10.1056/NEJM198012183032516] [PMID: 7432414]
[5]
Goldstein I, Burnett AL, Rosen RC, Park PW, Stecher VJ. The serendipitous story of sildenafil: An unexpected oral therapy for erectile dysfunction. Sex Med Rev 2019; 7(1): 115-28.
[http://dx.doi.org/10.1016/j.sxmr.2018.06.005] [PMID: 30301707]
[6]
Nuss GR, Rackley JD, Assimos DG. Adjunctive therapy to promote stone passage. Rev Urol 2005; 7(2): 67-74.
[PMID: 16985812]
[7]
Wikberg JE. Adrenergic receptors: classification, ligand binding and molecular properties. Acta Med Scand Suppl 1982; 665: 19-36.
[http://dx.doi.org/10.1111/j.0954-6820.1982.tb00405.x] [PMID: 6297264]
[8]
Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56(3): 331-49.
[http://dx.doi.org/10.1124/pr.56.3.1] [PMID: 15317907]
[9]
Sica DA. Alpha1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 2005; 7(12): 757-62.
[http://dx.doi.org/10.1111/j.1524-6175.2005.05300.x] [PMID: 16330901]
[10]
Whelton PK, Carey RM, Aronow WS. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines [published correction appears in hypertension. 2017; 71(6): 136-9.
[11]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension: the task force for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. J Hypertens 2018; 36(10): 1953-2041.
[http://dx.doi.org/10.1097/HJH.0000000000001940] [PMID: 30234752]
[12]
Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99(6): 1915-42.
[http://dx.doi.org/10.1210/jc.2014-1498] [PMID: 24893135]
[13]
Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122(2): 133-41.
[http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00010] [PMID: 7992988]
[14]
Levy D, Walmsley P, Levenstein M. Principal results of the Hypertension and Lipid Trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131(5): 966-73.
[http://dx.doi.org/10.1016/S0002-8703(96)90181-7] [PMID: 8615318]
[15]
Price D. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists. Eur Urol 2001; 40(Suppl. 4): 5-11.
[http://dx.doi.org/10.1159/000049889] [PMID: 11786674]
[16]
Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64(1): 118-40.
[http://dx.doi.org/10.1016/j.eururo.2013.03.004] [PMID: 23541338]
[17]
Roehrborn CG. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009; 11(Suppl. 1): S1-8.
[PMID: 20126606]
[18]
Weinberger MH, Fawzy A. Doxazosin in elderly patients with hypertension. Int J Clin Pract 2000; 54(3): 181-9.
[PMID: 10829361]
[19]
Conway JC, Friedman BW. Medical expulsive therapy (alpha blockers) for urologic stone disease. Acad Emerg Med 2020; 27(9): 923-4.
[http://dx.doi.org/10.1111/acem.13935] [PMID: 32034826]
[20]
Assimos D, Krambeck A, Miller NL, et al. Surgical management of stones: american urological association/endourological society guideline, part i. J Urol 2016; 196(4): 1153-60.
[http://dx.doi.org/10.1016/j.juro.2016.05.090] [PMID: 27238616]
[21]
Türk C, Petřík A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 2016; 69(3): 468-74.
[http://dx.doi.org/10.1016/j.eururo.2015.07.040] [PMID: 26318710]
[22]
Detweiler MB, Pagadala B, Candelario J, Boyle JS, Detweiler JG, Lutgens BW. Treatment of post-traumatic stress disorder nightmares at a veterans affairs medical center. J Clin Med 2016; 5(12): E117.
[http://dx.doi.org/10.3390/jcm5120117] [PMID: 27999253]
[23]
Yücel DE, van Emmerik AAP, Souama C, Lancee J. Comparative efficacy of imagery rehearsal therapy and prazosin in the treatment of trauma-related nightmares in adults: A meta-analysis of randomized controlled trials. Sleep Med Rev 2020; 50: 101248.
[http://dx.doi.org/10.1016/j.smrv.2019.101248] [PMID: 31855732]
[24]
Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Med 2020; 67: 225-31.
[http://dx.doi.org/10.1016/j.sleep.2019.06.010] [PMID: 31972510]
[25]
Smith C, Koola MM. Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder. Psychiatr Ann 2016; 46(9): 553-5.
[http://dx.doi.org/10.3928/00485713-20160728-01] [PMID: 27667865]
[26]
Cheah PY, Liong ML, Yuen KH, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003; 169(2): 592-6.
[http://dx.doi.org/10.1016/S0022-5347(05)63960-2] [PMID: 12544314]
[27]
Cohen JM, Fagin AP, Hariton E, et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One 2012; 7(8): e41941.
[http://dx.doi.org/10.1371/journal.pone.0041941] [PMID: 22870266]
[28]
Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 2016; 69(2): 286-97.
[http://dx.doi.org/10.1016/j.eururo.2015.08.061] [PMID: 26411805]
[29]
Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002; 60(4): 650-5.
[http://dx.doi.org/10.1016/S0090-4295(02)01840-X] [PMID: 12385927]
[30]
Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 1999; 45(3): 567-70.
[http://dx.doi.org/10.1016/S0360-3016(99)00232-1] [PMID: 10524407]
[31]
Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol 2010; 65(5): 565-70.
[http://dx.doi.org/10.1080/AC.65.5.2056244] [PMID: 21125979]
[32]
do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β-blockers: History, class differences and clinical applicability. Curr Hypertens Rev 2019; 15(1): 22-31.
[http://dx.doi.org/10.2174/1573402114666180918102735] [PMID: 30227820]
[33]
Weber MA. The role of the new beta-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18(12 Pt 2): 169S-76S.
[http://dx.doi.org/10.1016/j.amjhyper.2005.09.009] [PMID: 16373195]
[34]
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387(10022): 957-67.
[http://dx.doi.org/10.1016/S0140-6736(15)01225-8] [PMID: 26724178]
[35]
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64(18): 1929-49.
[http://dx.doi.org/10.1016/j.jacc.2014.07.017] [PMID: 25077860]
[36]
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130(25): e344-426. [Erratum in: Circulation. 2014 Dec 23;130 [25 [:e433-4. Dosage error in article text.
[PMID: 25249585] [http://dx.doi.org/10.1161/CIR.0000000000000134] [PMID: 25249585]
[37]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6): e137-61.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[38]
Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 2016; 133(14): e471-505. [Erratum in: Circulation. 2016 Sep 13;134 [11 [:e232-3.
[PMID: 26399662] [http://dx.doi.org/10.1161/CIR.0000000000000310] [PMID: 26399662]
[39]
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 2020; 142(25): e558-631. [Erratum in: Circulation. 2020 Dec 22;142] [25]. [:e633. PMID: 33215931].
[http://dx.doi.org/10.1161/CIR.0000000000000937] [PMID: 33215931]
[40]
Hiratzka LF, Bakris GL, Beckman JA, et al. ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Catheter Cardiovasc Interv 2010; 76(2): E43-86.
[http://dx.doi.org/10.1002/ccd.22537] [PMID: 20687249]
[41]
Geffner DL, Hershman JM. Beta-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93(1): 61-8.
[http://dx.doi.org/10.1016/0002-9343(92)90681-Z] [PMID: 1352658]
[42]
Feely J, Peden N. Use of beta-adrenoceptor blocking drugs in hyperthyroidism. Drugs 1984; 27(5): 425-46.
[http://dx.doi.org/10.2165/00003495-198427050-00003] [PMID: 6144501]
[43]
Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clin Proc 2019; 94(6): 1048-64.
[http://dx.doi.org/10.1016/j.mayocp.2018.10.011] [PMID: 30922695]
[44]
Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987; 317(14): 856-61. [Erratum in: N Engl J Med 1988 Apr 14;318]. [15] [:994.PMID: 3306385].
[http://dx.doi.org/10.1056/NEJM198710013171403] [PMID: 3306385]
[45]
Poynard T, Calès P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. N Engl J Med 1991; 324(22): 1532-8.
[http://dx.doi.org/10.1056/NEJM199105303242202] [PMID: 1674104]
[46]
Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 2004; 127(2): 476-84.
[http://dx.doi.org/10.1053/j.gastro.2004.05.004] [PMID: 15300580]
[47]
Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010; 52(3): 811-3.
[http://dx.doi.org/10.1002/hep.23852] [PMID: 20812354]
[48]
Sersté T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010; 52(3): 1017-22.
[http://dx.doi.org/10.1002/hep.23775] [PMID: 20583214]
[49]
Mandorfer M, Bota S, Schwabl P, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014; 146(7): 1680-90.e1.
[http://dx.doi.org/10.1053/j.gastro.2014.03.005] [PMID: 24631577]
[50]
Rosen JA. Observations on the efficacy of propranolol for the prophylaxis of migraine. Ann Neurol 1983; 13(1): 92-3.
[http://dx.doi.org/10.1002/ana.410130119] [PMID: 6338806]
[51]
Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010; 182(7): E269-76.
[http://dx.doi.org/10.1503/cmaj.081657] [PMID: 20159899]
[52]
Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52(3): 237-43.
[http://dx.doi.org/10.1046/j.0306-5251.2001.01459.x] [PMID: 11560555]
[53]
Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011; 77(19): 1752-5.
[http://dx.doi.org/10.1212/WNL.0b013e318236f0fd] [PMID: 22013182]
[54]
Koller WC, Hristova A, Brin M. Pharmacologic treatment of essential tremor. Neurology 2000; 54(11)(Suppl. 4): S30-8.
[PMID: 10854350]
[55]
Deuschl G, Raethjen J, Hellriegel H, Elble R. Treatment of patients with essential tremor. Lancet Neurol 2011; 10(2): 148-61.
[http://dx.doi.org/10.1016/S1474-4422(10)70322-7] [PMID: 21256454]
[56]
Koller WC. Long-acting propranolol in essential tremor. Neurology 1985; 35(1): 108-10.
[http://dx.doi.org/10.1212/WNL.35.1.108] [PMID: 3965982]
[57]
Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 1994; 14(5): 543-60.
[PMID: 7997388]
[58]
Irwin M, Sullivan G, Van Putten T. Propranolol as a primary treatment of neuroleptic-induced akathisia. Hillside J Clin Psychiatry 1988; 10(2): 244-50.
[PMID: 2906317]
[59]
Kim A, Adler L, Angrist B, Rotrosen J. Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1989; 9(4): 294-6.
[http://dx.doi.org/10.1097/00004714-198908000-00012] [PMID: 2570088]
[60]
Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology 2009; 116(7): 1243-9.
[http://dx.doi.org/10.1016/j.ophtha.2009.01.036] [PMID: 19450880]
[61]
van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005; 112(7): 1177-85.
[http://dx.doi.org/10.1016/j.ophtha.2005.01.042] [PMID: 15921747]
[62]
Brooks AM, Gillies WE. Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects. Drugs Aging 1992; 2(3): 208-21.
[http://dx.doi.org/10.2165/00002512-199202030-00005] [PMID: 1351412]
[63]
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clin Ophthalmol 2016; 10: 2433-41.
[http://dx.doi.org/10.2147/OPTH.S118409] [PMID: 27994437]
[64]
Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982; 307(26): 1618-27.
[http://dx.doi.org/10.1056/NEJM198212233072605] [PMID: 6292718]
[65]
Karlsberg RP. Calcium channel blockers for cardiovascular disorders. Arch Intern Med 1982; 142(3): 452-5.
[http://dx.doi.org/10.1001/archinte.1982.00340160036009] [PMID: 6279045]
[66]
Triggle DJ. Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev Technol 2003; 1(5): 719-33.
[http://dx.doi.org/10.1089/154065803770381075] [PMID: 15090244]
[67]
Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341(19): 1447-57.
[http://dx.doi.org/10.1056/NEJM199911043411907] [PMID: 10547409]
[68]
Kahan A, Amor B, Menkès CJ, Weber S, Guérin F, Degeorges M. Nicardipine in the treatment of Raynaud’s phenomenon: a randomized double-blind trial. Angiology 1987; 38(4): 333-7.
[http://dx.doi.org/10.1177/000331978703800407] [PMID: 3555175]
[69]
Rodeheffer RJ, Rommer JA, Wigley F, Smith CR. Controlled double-blind trial of nifedipine in the treatment of Raynaud’s phenomenon. N Engl J Med 1983; 308(15): 880-3.
[http://dx.doi.org/10.1056/NEJM198304143081507] [PMID: 6339921]
[70]
Rirash F, Tingey PC, Harding SE, et al. Calcium channel blockers for primary and secondary Raynaud’s phenomenon. Cochrane Database Syst Rev 2017; 12(12): CD000467.
[http://dx.doi.org/10.1002/14651858.CD000467.pub2] [PMID: 29237099]
[71]
La Civita L, Pitaro N, Rossi M, et al. Amlodipine in the treatment of Raynaud’s phenomenon. Br J Rheumatol 1993; 32(6): 524-5.
[http://dx.doi.org/10.1093/rheumatology/32.6.524-a] [PMID: 8508292]
[72]
Gjørup T, Hartling OJ, Kelbaek H, Nielsen SL. Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud’s phenomenon. Eur J Clin Pharmacol 1986; 31(4): 387-9.
[http://dx.doi.org/10.1007/BF00613511] [PMID: 3816916]
[73]
Leppert J, Jonasson T, Nilsson H, Ringqvist I. The effect of isradipine, a new calcium-channel antagonist, in patients with primary Raynaud’s phenomenon: a single-blind dose-response study. Cardiovasc Drugs Ther 1989; 3(3): 397-401.
[http://dx.doi.org/10.1007/BF01858110] [PMID: 2535054]
[74]
Hinze AM, Wigley FM. Pharmacotherapy options in the management of raynaud’s phenomenon. Curr Treatm Opt Rheumatol 2018; 4(3): 235-54.
[http://dx.doi.org/10.1007/s40674-018-0102-6] [PMID: 31538045]
[75]
Khaledifar B, Mahmoudi MY, Mobasheri M. A double-blind randomized trial comparing the effectiveness and safety of nifedipine and isosorbide dinitrate in chronic anal fissure. Malays J Med Sci 2015; 22(5): 42-9.
[PMID: 28239267]
[76]
Ezri T, Susmallian S. Topical nifedipine vs. topical glyceryl trinitrate for treatment of chronic anal fissure. Dis Colon Rectum 2003; 46(6): 805-8.
[http://dx.doi.org/10.1007/s10350-004-6660-8] [PMID: 12794583]
[77]
Knight JS, Birks M, Farouk R. Topical diltiazem ointment in the treatment of chronic anal fissure. Br J Surg 2001; 88(4): 553-6.
[http://dx.doi.org/10.1046/j.1365-2168.2001.01736.x] [PMID: 11298624]
[78]
Jonas M, Speake W, Scholefield JH. Diltiazem heals glyceryl trinitrate-resistant chronic anal fissures: a prospective study. Dis Colon Rectum 2002; 45(8): 1091-5.
[http://dx.doi.org/10.1007/s10350-004-6365-z] [PMID: 12195195]
[79]
Agrawal V, Kaushal G, Gupta R. Randomized controlled pilot trial of nifedipine as oral therapy vs. topical application in the treatment of fissure-in-ano. Am J Surg 2013; 206(5): 748-51.
[http://dx.doi.org/10.1016/j.amjsurg.2013.05.003] [PMID: 24035211]
[80]
Sahebally SM, Ahmed K, Cerneveciute R, Iqbal A, Walsh SR, Joyce MR. Oral versus topical calcium channel blockers for chronic anal fissure-a systematic review and meta-analysis of randomized controlled trials. Int J Surg 2017; 44: 87-93.
[http://dx.doi.org/10.1016/j.ijsu.2017.06.039] [PMID: 28629764]
[81]
Cook TA, Humphreys MM, McC Mortensen NJ. Oral nifedipine reduces resting anal pressure and heals chronic anal fissure. Br J Surg 1999; 86(10): 1269-73.
[http://dx.doi.org/10.1046/j.1365-2168.1999.01292.x] [PMID: 10540130]
[82]
Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA 1983; 250(18): 2500-2.
[http://dx.doi.org/10.1001/jama.1983.03340180054025] [PMID: 6355533]
[83]
Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 2019; 160(4): 762-72.
[http://dx.doi.org/10.1097/j.pain.0000000000001456] [PMID: 30699098]
[84]
Solomon GD. Comparative efficacy of calcium antagonist drugs in the prophylaxis of migraine. Headache 1985; 25(7): 368-71.
[http://dx.doi.org/10.1111/j.1526-4610.1985.hed2507368.x] [PMID: 3908401]
[85]
Meyer JS, Hardenberg J. Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches. Headache 1983; 23(6): 266-77.
[http://dx.doi.org/10.1111/j.1526-4610.1983.hed2306266.x] [PMID: 6358126]
[86]
Cattau EL Jr, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol 1991; 86(3): 272-6.
[PMID: 1998307]
[87]
Valdovinos MA, Zavala-Solares MR, Coss-Adame E. Esophageal hypomotility and spastic motor disorders: current diagnosis and treatment. Curr Gastroenterol Rep 2014; 16(11): 421.
[http://dx.doi.org/10.1007/s11894-014-0421-1] [PMID: 25376746]
[88]
Cao D, Yang L, Liu L, et al. A comparison of nifedipine and tamsulosin as medical expulsive therapy for the management of lower ureteral stones without ESWL. Sci Rep 2014; 4: 5254.
[http://dx.doi.org/10.1038/srep05254] [PMID: 24919112]
[89]
Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 2009; 56(3): 455-71.
[http://dx.doi.org/10.1016/j.eururo.2009.06.012] [PMID: 19560860]
[90]
King JF, Flenady V, Papatsonis D, Dekker G, Carbonne B. Calcium channel blockers for inhibiting preterm labour; a systematic review of the evidence and a protocol for administration of nifedipine. Aust N Z J Obstet Gynaecol 2003; 43(3): 192-8.
[http://dx.doi.org/10.1046/j.0004-8666.2003.00074.x] [PMID: 14712983]
[91]
Oelz O, Maggiorini M, Ritter M, et al. Prevention and treatment of high altitude pulmonary edema by a calcium channel blocker. Int J Sports Med 1992; 13(Suppl. 1): S65-8.
[http://dx.doi.org/10.1055/s-2007-1024598] [PMID: 1483797]
[92]
Bärtsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991; 325(18): 1284-9.
[http://dx.doi.org/10.1056/NEJM199110313251805] [PMID: 1922223]
[93]
Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog Cardiovasc Dis 2010; 52(6): 500-6.
[http://dx.doi.org/10.1016/j.pcad.2010.03.001] [PMID: 20417343]
[94]
Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor- grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg 1988; 68(4): 505-17.
[http://dx.doi.org/10.3171/jns.1988.68.4.0505] [PMID: 3280746]
[95]
Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; (3): CD000277.
[http://dx.doi.org/10.1002/14651858.CD000277.pub3] [PMID: 17636626]
[96]
Sketris IS, Methot ME, Nicol D, Belitsky P, Knox MG. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28(11): 1227-31.
[http://dx.doi.org/10.1177/106002809402801101] [PMID: 7849332]
[97]
Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DW. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994; 14(4): 471-81.
[PMID: 7937285]
[98]
Abrams J. Hemodynamic effects of nitroglycerin and long-acting nitrates. Am Heart J 1985; 110(1 Pt 2): 216-24.
[http://dx.doi.org/10.1016/0002-8703(85)90490-9] [PMID: 3925741]
[99]
Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 1992; 70(8): 30B-42B.
[http://dx.doi.org/10.1016/0002-9149(92)90592-M] [PMID: 1529924]
[100]
Pavasini R, Camici PG, Crea F, et al. Anti-anginal drugs: Systematic review and clinical implications. Int J Cardiol 2019; 283: 55-63. [Erratum in: Int J Cardiol. 2020 Dec 15;321:23. PMID: 30538056].
[http://dx.doi.org/10.1016/j.ijcard.2018.12.008] [PMID: 30538056]
[101]
Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281(20): 1927-36.
[http://dx.doi.org/10.1001/jama.281.20.1927] [PMID: 10349897]
[102]
Knight CJ, Panesar M, Wilson DJ, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95(1): 125-32.
[http://dx.doi.org/10.1161/01.CIR.95.1.125] [PMID: 8994427]
[103]
Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol 1992; 70(8): 18B-22B.
[http://dx.doi.org/10.1016/0002-9149(92)90590-U] [PMID: 1529922]
[104]
Gorfine SR. Topical nitroglycerin therapy for anal fissures and ulcers. N Engl J Med 1995; 333(17): 1156-7.
[http://dx.doi.org/10.1056/NEJM199510263331718] [PMID: 7565967]
[105]
Altomare DF, Rinaldi M, Milito G, et al. Glyceryl trinitrate for chronic anal fissure-healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum 2000; 43(2): 174-9.
[http://dx.doi.org/10.1007/BF02236977] [PMID: 10696890]
[106]
Nelson RL, Thomas K, Morgan J, Jones A. Non surgical therapy for anal fissure. Cochrane Database Syst Rev 2012; (2): CD003431.
[http://dx.doi.org/10.1002/14651858.CD003431.pub3] [PMID: 22336789]
[107]
Hong RW, Greenfield ML, Polley LS. Nitroglycerin for uterine inversion in the absence of placental fragments. Anesth Analg 2006; 103(2): 511-2.
[http://dx.doi.org/10.1213/01.ANE.0000227115.35626.09] [PMID: 16861471]
[108]
Peng AT, Gorman RS, Shulman SM, DeMarchis E, Nyunt K, Blancato LS. Intravenous nitroglycerin for uterine relaxation in the postpartum patient with retained placenta. Anesthesiology 1989; 71(1): 172-3.
[http://dx.doi.org/10.1097/00000542-198907000-00039] [PMID: 2502047]
[109]
Chandraharan E, Arulkumaran S. Acute tocolysis. Curr Opin Obstet Gynecol 2005; 17(2): 151-6.
[http://dx.doi.org/10.1097/01.gco.0000162184.45854.88] [PMID: 15758607]
[110]
Denison FC, Carruthers KF, Hudson J, et al. Glyceryl trinitrate to reduce the need for manual removal of retained placenta following vaginal delivery: the GOT-IT RCT. Health Technol Assess 2019; 23(70): 1-72.
[http://dx.doi.org/10.3310/hta23700] [PMID: 31912780]
[111]
Plum M, Moukhachen O. Alternative pharmacological management of vasopressor extravasation in the absence of phentolamine. P&T 2017; 42(9): 581-92.
[PMID: 28890646]
[112]
Shrestha N, Acharya U, Shrestha PS, Acharya SP, Karki B, Dhakal SS. Topical nitroglycerin for management of peripheral extravasation of vasopressors: A case report. Oxf Med Case Reports 2020.
[http://dx.doi.org/10.1093/omcr/omaa066]
[113]
Denkler KA, Cohen BE. Reversal of dopamine extravasation injury with topical nitroglycerin ointment. Plast Reconstr Surg 1989; 84(5): 811-3.
[http://dx.doi.org/10.1097/00006534-198911000-00017] [PMID: 2510208]
[114]
Curtiss P, Schwager Z, Cobos G, Lo Sicco K, Franks AG Jr. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon. J Am Acad Dermatol 2018; 78(6): 1110-1118.e3.
[http://dx.doi.org/10.1016/j.jaad.2018.01.043] [PMID: 29408338]
[115]
Qiu O, Chan T, Luen M, Cruz JE, Hermes-DeSantis ER. Use of nitroglycerin ointment to treat primary and secondary Raynaud’s phenomenon: a systematic literature review. Rheumatol Int 2018; 38(12): 2209-16.
[http://dx.doi.org/10.1007/s00296-018-4119-9] [PMID: 30155665]
[116]
Linnemann B, Erbe M. Raynaud’s phenomenon and digital ischaemia-pharmacologic approach and alternative treatment options. Vasa 2016; 45(3): 201-12.
[http://dx.doi.org/10.1024/0301-1526/a000526] [PMID: 27129065]
[117]
Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56(1): 124-30.
[http://dx.doi.org/10.1124/mol.56.1.124] [PMID: 10385692]
[118]
Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009; 361(19): 1864-71.
[http://dx.doi.org/10.1056/NEJMct0904473] [PMID: 19890129]
[119]
Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. Cochrane Database Syst Rev 2019; 1(1): CD012621.
[http://dx.doi.org/10.1002/14651858.CD012621.pub2] [PMID: 30701543]
[120]
Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26(9): 813-25.
[http://dx.doi.org/10.1007/s12325-009-0064-z] [PMID: 19768639]
[121]
Lue TF. Erectile dysfunction. N Engl J Med 2000; 342(24): 1802-13.
[http://dx.doi.org/10.1056/NEJM200006153422407] [PMID: 10853004]
[122]
Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63(5): 902-12.
[http://dx.doi.org/10.1016/j.eururo.2013.01.012] [PMID: 23395275]
[123]
Toda N, Ayajiki K, Okamura T. Nitric oxide and penile erectile function. Pharmacol Ther 2005; 106(2): 233-66.
[http://dx.doi.org/10.1016/j.pharmthera.2004.11.011] [PMID: 15866322]
[124]
Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999; 281(5): 421-6.
[http://dx.doi.org/10.1001/jama.281.5.421] [PMID: 9952201]
[125]
Blonde L. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006; 22(11): 2111-20.
[http://dx.doi.org/10.1185/030079906X148256] [PMID: 17076971]
[126]
Del Popolo G, Cito G, Gemma L, Natali A. Neurogenic sexual dysfunction treatment: A systematic review. Eur Urol Focus 2020; 6(5): 868-76.
[http://dx.doi.org/10.1016/j.euf.2019.12.002] [PMID: 31879263]
[127]
Schmid DM, Schurch B, Hauri D. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. Eur Urol 2000; 38(2): 184-93.
[http://dx.doi.org/10.1159/000020278] [PMID: 10895011]
[128]
Schover LR, Fouladi RT, Warneke CL, et al. The use of treatments for erectile dysfunction among survivors of prostate carcinoma. Cancer 2002; 95(11): 2397-407.
[http://dx.doi.org/10.1002/cncr.10970] [PMID: 12436448]
[129]
Montorsi F, McCullough A. Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. J Sex Med 2005; 2(5): 658-67.
[http://dx.doi.org/10.1111/j.1743-6109.2005.00117.x] [PMID: 16422824]
[130]
Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52(6): 963-6.
[http://dx.doi.org/10.1016/S0090-4295(98)00443-9] [PMID: 9836537]
[131]
Harrington C, Campbell G, Wynne C, Atkinson C. Randomised, placebo-controlled, crossover trial of sildenafil citrate in the treatment of erectile dysfunction following external beam radiation treatment of prostate cancer. J Med Imaging Radiat Oncol 2010; 54(3): 224-8.
[http://dx.doi.org/10.1111/j.1754-9485.2010.02168.x] [PMID: 20598010]
[132]
Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut 2002; 50(6): 758-64.
[http://dx.doi.org/10.1136/gut.50.6.758] [PMID: 12010875]
[133]
Fox M, Sweis R, Wong T, Anggiansah A. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol Motil 2007; 19(10): 798-803.
[http://dx.doi.org/10.1111/j.1365-2982.2007.00957.x] [PMID: 17883431]
[134]
Hachulla E, Hatron PY, Carpentier P, et al. Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 2016; 75(6): 1009-15.
[http://dx.doi.org/10.1136/annrheumdis-2014-207001] [PMID: 25995322]
[135]
Tingey T, Shu J, Smuczek J, Pope J. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res (Hoboken) 2013; 65(9): 1460-71.
[http://dx.doi.org/10.1002/acr.22018] [PMID: 23554239]
[136]
Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology (Oxford) 2017; 56(1): 14-25.
[http://dx.doi.org/10.1093/rheumatology/kew047] [PMID: 27094599]
[137]
Shenoy PD, Kumar S, Jha LK, et al. Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010; 49(12): 2420-8.
[http://dx.doi.org/10.1093/rheumatology/keq291] [PMID: 20837499]
[138]
Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005; 112(19): 2980-5.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.523324] [PMID: 16275885]
[139]
Xu Y, Liu Y, Liu J, Qian G. Meta-analysis of clinical efficacy of sildenafil, a phosphodiesterase type-5 inhibitor on high altitude hypoxia and its complications. High Alt Med Biol 2014; 15(1): 46-51.
[http://dx.doi.org/10.1089/ham.2013.1110] [PMID: 24673534]
[140]
Richalet JP, Gratadour P, Robach P, et al. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 2005; 171(3): 275-81.
[http://dx.doi.org/10.1164/rccm.200406-804OC] [PMID: 15516532]
[141]
Perimenis P. Sildenafil for the treatment of altitude-induced hypoxaemia. Expert Opin Pharmacother 2005; 6(5): 835-7.
[http://dx.doi.org/10.1517/14656566.6.5.835] [PMID: 15934909]
[142]
Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145(7): 497-506.
[http://dx.doi.org/10.7326/0003-4819-145-7-200610030-00007] [PMID: 17015867]
[143]
Navar LG. Physiology: hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system. J Am Soc Hypertens 2014; 8(7): 519-24.
[http://dx.doi.org/10.1016/j.jash.2014.05.014] [PMID: 25064774]
[144]
Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int 1991; 40(4): 583-96.
[http://dx.doi.org/10.1038/ki.1991.249] [PMID: 1745006]
[145]
Takeda Y, Miyamori I, Yoneda T, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81(8): 2797-800.
[http://dx.doi.org/10.1210/jcem.81.8.8768832] [PMID: 8768832]
[146]
Weber KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 1997; 96(11): 4065-82.
[http://dx.doi.org/10.1161/01.CIR.96.11.4065] [PMID: 9403633]
[147]
Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 2004; 1(2): 45-50.
[http://dx.doi.org/10.1007/s11897-004-0024-5] [PMID: 16036024]
[148]
Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009; 93(3): 569-82.
[http://dx.doi.org/10.1016/j.mcna.2009.02.014] [PMID: 19427492]
[149]
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23): 1429-35.
[http://dx.doi.org/10.1056/NEJM198706043162301] [PMID: 2883575]
[150]
Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5): 293-302.
[http://dx.doi.org/10.1056/NEJM199108013250501] [PMID: 2057034]
[151]
Rutherford JD, Pfeffer MA, Moyé LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. Circulation 1994; 90(4): 1731-8.
[http://dx.doi.org/10.1161/01.CIR.90.4.1731] [PMID: 7923656]
[152]
Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333(25): 1670-6.
[http://dx.doi.org/10.1056/NEJM199512213332503] [PMID: 7477219]
[153]
The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342(8875): 821-8.
[PMID: 8104270]
[154]
Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72(2): 406-12.
[http://dx.doi.org/10.1161/01.CIR.72.2.406] [PMID: 3891136]
[155]
Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin 2014; 32(1): 21-32.
[http://dx.doi.org/10.1016/j.ccl.2013.09.002]
[156]
Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327(10): 669-77.
[http://dx.doi.org/10.1056/NEJM199209033271001] [PMID: 1386652]
[157]
Roscioni SS, Heerspink HJ, de Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 2014; 10(2): 77-87. [Erratum in: Nat Rev Nephrol. 2014 May;10]. [5]. [:243. PMID: 24296623].
[http://dx.doi.org/10.1038/nrneph.2013.251] [PMID: 24296623]
[158]
Cordonnier DJ, Zaoui P, Halimi S. Role of ACE inhibitors in patients with diabetes mellitus. Drugs 2001; 61(13): 1883-92.
[http://dx.doi.org/10.2165/00003495-200161130-00001] [PMID: 11708761]
[159]
Barnett AH. The Heart Outcomes Protection Evaluation (HOPE) study: relevance to ophthalmological practice? Eye (Lond) 2000; 14(Pt 1): 1-2.
[http://dx.doi.org/10.1038/eye.2000.1] [PMID: 10755090]
[160]
Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ. Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997; 46(4): 665-70.
[http://dx.doi.org/10.2337/diab.46.4.665] [PMID: 9075809]
[161]
Malik RA. Can diabetic neuropathy be prevented by angiotensin- converting enzyme inhibitors? Ann Med 2000; 32(1): 1-5.
[http://dx.doi.org/10.3109/07853890008995903] [PMID: 10711571]
[162]
Coppey LJ, Davidson EP, Rinehart TW, et al. ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats. Diabetes 2006; 55(2): 341-8.
[http://dx.doi.org/10.2337/diabetes.55.02.06.db05-0885] [PMID: 16443766]
[163]
Ueno S, Hamada T, Taniguchi S, et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: Cross-sectional cohort study. Drug Res (Stuttg) 2016; 66(12): 628-32.
[http://dx.doi.org/10.1055/s-0042-113183] [PMID: 27643410]
[164]
Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003; 17(5-6): 397-414.
[http://dx.doi.org/10.1023/B:CARD.0000015855.02485.e3]
[165]
Sassi KLM, Martins LB, de Miranda AS, Teixeira AL. Renin-angiotensin-aldosterone system and migraine: A systematic review of human studies. Protein Pept Lett 2020; 27(6): 512-9.
[http://dx.doi.org/10.2174/0929866527666200129160136] [PMID: 31995000]
[166]
Dorosch T, Ganzer CA, Lin M, Seifan A. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. Curr Pain Headache Rep 2019; 23(11): 85.
[http://dx.doi.org/10.1007/s11916-019-0823-8] [PMID: 31515634]
[167]
Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: An enigma revisited. Am J Kidney Dis 1994; 24(1): 1-11.
[http://dx.doi.org/10.1016/S0272-6386(12)80153-3] [PMID: 8023814]
[168]
Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int 2003; 63(4): 1187-94.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00850.x] [PMID: 12631334]
[169]
Glicklich D, Burris L, Urban A, et al. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis. J Am Soc Nephrol 2001; 12(9): 1958-64.
[http://dx.doi.org/10.1681/ASN.V1291958] [PMID: 11518790]
[170]
Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7(10): 2350-60.
[http://dx.doi.org/10.1111/j.1600-6143.2007.01928.x] [PMID: 17845569]
[171]
Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9(5): 399-405.
[http://dx.doi.org/10.1111/j.1524-6175.2007.07161.x] [PMID: 17485976]
[172]
Taddei S. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Am J Cardiovasc Drugs 2015; 15(3): 185-94.
[http://dx.doi.org/10.1007/s40256-015-0116-5] [PMID: 25850749]
[173]
Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38(12): 1551-9.
[http://dx.doi.org/10.1097/00004583-199912000-00017] [PMID: 10596256]
[174]
Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009; 48(9): 884-93.
[http://dx.doi.org/10.1097/CHI.0b013e3181b26e9f] [PMID: 19625978]
[175]
Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog 2015; 62(1): 31-9.
[http://dx.doi.org/10.2344/0003-3006-62.1.31] [PMID: 25849473]
[176]
Kreidler MC, Briscoe LA, Beech RR. Pharmacology for post-traumatic stress disorder related to childhood sexual abuse: a literature review. Perspect Psychiatr Care 2002; 38(4): 135-45.
[http://dx.doi.org/10.1111/j.1744-6163.2002.tb01564.x] [PMID: 12629952]
[177]
Prince JB, Wilens TE, Biederman J, Spencer TJ, Wozniak JR. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry 1996; 35(5): 599-605.
[http://dx.doi.org/10.1097/00004583-199605000-00014] [PMID: 8935206]
[178]
Wilens TE, Biederman J, Spencer T. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1994; 33(3): 424-6.
[http://dx.doi.org/10.1097/00004583-199403000-00018] [PMID: 8169189]
[179]
Gowing L, Farrell M, Ali R, White JM. Alpha₂-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2016; (5): CD002024.
[http://dx.doi.org/10.1002/14651858.CD002024.pub5] [PMID: 27140827]
[180]
Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295(17): 2057-71.
[http://dx.doi.org/10.1001/jama.295.17.2057] [PMID: 16670414]
[181]
Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000; 132(10): 788-93.
[http://dx.doi.org/10.7326/0003-4819-132-10-200005160-00004] [PMID: 10819701]
[182]
Gagnon DJ, Riker RR, Glisic EK, Kelner A, Perrey HM, Fraser GL. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy 2015; 35(3): 251-9.
[http://dx.doi.org/10.1002/phar.1559] [PMID: 25809176]
[183]
Bhatt K, Thompson Quan A, Baumgartner L, et al. Effects of a clonidine taper on dexmedetomidine use and withdrawal in adult critically ill patients-a pilot study. Crit Care Explor 2020; 2(11): e0245.
[http://dx.doi.org/10.1097/CCE.0000000000000245] [PMID: 33163969]
[184]
Glaess SS, Attridge RL, Christina Gutierrez G. Clonidine as a strategy for discontinuing dexmedetomidine sedation in critically ill patients: A narrative review. Am J Health Syst Pharm 2020; 77(7): 515-22.
[http://dx.doi.org/10.1093/ajhp/zxaa013] [PMID: 32086509]
[185]
DiNicolantonio JJ, Bhutani J, Lavie CJ, O’Keefe JH. Evidence-based diuretics: focus on chlorthalidone and indapamide. Future Cardiol 2015; 11(2): 203-17.
[http://dx.doi.org/10.2217/fca.14.83] [PMID: 25760879]
[186]
Nijenhuis T, Hoenderop JG, Loffing J, van der Kemp AW, van Os CH, Bindels RJ. Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int 2003; 64(2): 555-64.
[http://dx.doi.org/10.1046/j.1523-1755.2003.00128.x] [PMID: 12846750]
[187]
Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005; 115(6): 1651-8.
[http://dx.doi.org/10.1172/JCI24134] [PMID: 15902302]
[188]
Escribano J, Balaguer A, Pagone F, Feliu A, Roqué I Figuls M, Figuls M. Pharmacological interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev 2009; (1): CD004754.
[http://dx.doi.org/10.1002/14651858.CD004754.pub2] [PMID: 19160242]
[189]
Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993; 22(Suppl. 6): S78-86.
[http://dx.doi.org/10.1097/00005344-199312050-00014] [PMID: 7508066]
[190]
Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. Ann Intern Med 2013; 158(7): 535-43. [Erratum in: Ann Intern Med. 2013 Aug 6;159]. [3]. [:230-2. PMID: 23546565].
[http://dx.doi.org/10.7326/0003-4819-158-7-201304020-00005] [PMID: 23546565]
[191]
Refardt J, Winzeler B, Christ-Crain M. Diabetes insipidus: An update. Endocrinol Metab Clin North Am 2020; 49(3): 517-31.
[http://dx.doi.org/10.1016/j.ecl.2020.05.012] [PMID: 32741486]
[192]
Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 2020; 75(6): 1334-57.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026] [PMID: 32370572]
[193]
Carey RM. Special Article - The management of resistant hypertension: A 2020 update. Prog Cardiovasc Dis 2020; 63(5): 662-70.
[http://dx.doi.org/10.1016/j.pcad.2020.08.001] [PMID: 32795462]
[194]
Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150(2): 186-94.
[http://dx.doi.org/10.1111/j.1365-2133.2004.05785.x] [PMID: 14996087]
[195]
Lachgar S, Charveron M, Gall Y, Bonafe JL. Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells. Br J Dermatol 1998; 138(3): 407-11.
[http://dx.doi.org/10.1046/j.1365-2133.1998.02115.x] [PMID: 9580790]
[196]
Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000 Res 2017; 6: 1650.
[http://dx.doi.org/10.12688/f1000research.11775.1] [PMID: 29167734]
[197]
Hordinsky MK. Medical treatment of noncicatricial alopecia. Semin Cutan Med Surg 2006; 25(1): 51-5.
[http://dx.doi.org/10.1016/j.sder.2006.01.007] [PMID: 16616303]
[198]
Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-label use of topical minoxidil in alopecia: a review. Am J Clin Dermatol 2019; 20(2): 237-50.
[http://dx.doi.org/10.1007/s40257-018-0409-y] [PMID: 30604379]
[199]
Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: A review and clinical approach. J Am Acad Dermatol 2019; 81(2): 568-80.
[http://dx.doi.org/10.1016/j.jaad.2019.03.079] [PMID: 30953702]
[200]
Rodriguez R, Machiavelli M, Leone B, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 1994; 5(8): 769-70.
[http://dx.doi.org/10.1093/oxfordjournals.annonc.a058986] [PMID: 7826913]
[201]
Duvic M, Lemak NA, Valero V, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 1996; 35(1): 74-8.
[http://dx.doi.org/10.1016/S0190-9622(96)90500-9] [PMID: 8682968]
[202]
Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther 2004; 17(2): 164-76.
[http://dx.doi.org/10.1111/j.1396-0296.2004.04017.x] [PMID: 15113284]
[203]
Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol 2007; 21(3): 433-4.
[http://dx.doi.org/10.1111/j.1468-3083.2006.01933.x] [PMID: 17309495]
[204]
Price VH. Topical minoxidil in extensive alopecia areata, including 3-year follow-up. Dermatologica 1987; 175(Suppl. 2): 36-41.
[http://dx.doi.org/10.1159/000248901] [PMID: 3691913]
[205]
Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J (Clin Res Ed) 1983; 287(6398): 1015-7.
[http://dx.doi.org/10.1136/bmj.287.6398.1015] [PMID: 6412929]
[206]
Fiedler-Weiss VC. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987; 16(3 Pt 2): 745-8.
[http://dx.doi.org/10.1016/S0190-9622(87)80003-8] [PMID: 3549811]
[207]
Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action. Endocrinology 1975; 97(1): 52-8.
[http://dx.doi.org/10.1210/endo-97-1-52] [PMID: 166833]
[208]
De Gendt Karel, Verhoeven Guido. Tissue-and cell-specific functions of the androgen receptor revealed through conditional knockout models in mice. Molecular and cellular endocrinology 2012; 13-25.
[http://dx.doi.org/10.1016/j.mce.2011.08.008]
[209]
Danjuma Mohammed I. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Current hypertension reports 2014; 414.
[http://dx.doi.org/10.1007/s11906-013-0414-8]
[210]
Salavastru C M, Fritz K, Tiplica G S. Spironolactone in dermatological treatment. On and off label indications. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2013; 762-7.
[211]
Sabbadin C, Andrisani A, Zermiani M, et al. Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. J Endocrinol Invest 2016; 39(9): 1015-21.
[http://dx.doi.org/10.1007/s40618-016-0466-0] [PMID: 27072668]
[212]
Zouboulis CC, Akamatsu H, Stephanek K, Orfanos CE. Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol 1994; 7(1-2): 33-40.
[http://dx.doi.org/10.1159/000211271] [PMID: 8003320]
[213]
Brown J, Farquhar C, Lee O, Toomath R, Jepson RG. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2009; (2): CD000194.
[http://dx.doi.org/10.1002/14651858.CD000194.pub2] [PMID: 19370553]
[214]
Charny JW, Choi JK, James WD. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients. Int J Womens Dermatol 2017; 3(2): 111-5.
[http://dx.doi.org/10.1016/j.ijwd.2016.12.002] [PMID: 28560306]
[215]
Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1986; 115(2): 227-32.
[http://dx.doi.org/10.1111/j.1365-2133.1986.tb05722.x] [PMID: 2943311]
[216]
Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol 2005; 19(2): 163-6.
[http://dx.doi.org/10.1111/j.1468-3083.2005.01072.x] [PMID: 15752283]
[217]
Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2018; 103(4): 1258-64.
[http://dx.doi.org/10.1210/jc.2017-02052] [PMID: 29522176]
[218]
Koulouri O, Conway GS. A systematic review of commonly used medical treatments for hirsutism in women. Clin Endocrinol (Oxf) 2008; 68(5): 800-5.
[http://dx.doi.org/10.1111/j.1365-2265.2007.03105.x] [PMID: 17980017]
[219]
Ganie MA, Khurana ML, Nisar S, et al. Improved efficacy of low- dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. J Clin Endocrinol Metab 2013; 98(9): 3599-607.
[http://dx.doi.org/10.1210/jc.2013-1040] [PMID: 23846820]
[220]
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol 2005; 152(3): 466-73.
[http://dx.doi.org/10.1111/j.1365-2133.2005.06218.x] [PMID: 15787815]
[221]
Burke BM, Cunliffe WJ. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Br J Dermatol 1985; 112(1): 124-5.
[http://dx.doi.org/10.1111/j.1365-2133.1985.tb02305.x] [PMID: 3155956]
[222]
Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol 2007; 48(1): 43-5.
[http://dx.doi.org/10.1111/j.1440-0960.2007.00332.x] [PMID: 17222303]
[223]
Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf) 1997; 47(6): 759-60.
[http://dx.doi.org/10.1046/j.1365-2265.1997.3761162.x] [PMID: 9497885]
[224]
Lee A, Fischer G. A case series of 20 women with hidradenitis suppurativa treated with spironolactone. Australas J Dermatol 2015; 56(3): 192-6.
[http://dx.doi.org/10.1111/ajd.12362] [PMID: 26080895]
[225]
Golbari NM, Porter ML, Kimball AB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2019; 80(1): 114-9.
[http://dx.doi.org/10.1016/j.jaad.2018.06.063] [PMID: 30003993]
[226]
Quinlan C, Kirby B, Hughes R. Spironolactone therapy for hidradenitis suppurativa. Clin Exp Dermatol 2020; 45(4): 464-5.
[http://dx.doi.org/10.1111/ced.14119] [PMID: 31602704]
[227]
Laue L, Kenigsberg D, Pescovitz OH, et al. Treatment of familial male precocious puberty with spironolactone and testolactone. N Engl J Med 1989; 320(8): 496-502.
[http://dx.doi.org/10.1056/NEJM198902233200805] [PMID: 2492636]
[228]
Leschek EW, Jones J, Barnes KM, Hill SC, Cutler GB Jr. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 1999; 84(1): 175-8.
[http://dx.doi.org/10.1210/jcem.84.1.5413] [PMID: 9920079]